PMID- 26686866
OWN - NLM
STAT- MEDLINE
DCOM- 20161104
LR  - 20161230
IS  - 1747-4094 (Electronic)
IS  - 1747-4094 (Linking)
VI  - 9
IP  - 2
DP  - 2016
TI  - Andexanet alfa for the reversal of Factor Xa inhibitor related anticoagulation.
PG  - 115-22
LID - 10.1586/17474086.2016.1135046 [doi]
AB  - Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The 
      molecule is a recombinant protein analog of factor Xa that binds to Factor Xa 
      inhibitors and antithrombin:LMWH complex but does not trigger prothrombotic 
      activity. In ex vivo, animal, and volunteer human studies, andexanet alfa (AnXa) 
      was able to dose-dependently reverse Factor Xa inhibition and restore thrombin 
      generation for the duration of drug administration. Further trials are underway 
      to examine its safety and efficacy in the population of patients experiencing FXa 
      inhibitor-related bleeding.
FAU - Ghadimi, Kamrouz
AU  - Ghadimi K
AD  - a Divisions of Cardiothoracic Anesthesiology & Critical Care Medicine , Duke 
      University Medical Center , Durham , NC , USA.
FAU - Dombrowski, Keith E
AU  - Dombrowski KE
AD  - b Department of Neurology , Duke University Medical Center , Durham , NC , USA.
FAU - Levy, Jerrold H
AU  - Levy JH
AD  - a Divisions of Cardiothoracic Anesthesiology & Critical Care Medicine , Duke 
      University Medical Center , Durham , NC , USA.
FAU - Welsby, Ian J
AU  - Welsby IJ
AD  - a Divisions of Cardiothoracic Anesthesiology & Critical Care Medicine , Duke 
      University Medical Center , Durham , NC , USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Rev Hematol
JT  - Expert review of hematology
JID - 101485942
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (PRT064445)
RN  - 0 (Recombinant Proteins)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Animals
MH  - Blood Coagulation/*drug effects
MH  - Clinical Trials, Phase I as Topic
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
MH  - Drug Evaluation, Preclinical
MH  - Factor Xa/metabolism/*pharmacology/*therapeutic use
MH  - Factor Xa Inhibitors/*metabolism
MH  - Humans
MH  - Protein Binding
MH  - Recombinant Proteins/metabolism/*pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Andexanet alfa
OT  - Apixaban
OT  - Factor Xa inhibitors
OT  - Hemostasis
OT  - Morpholines
OT  - Prothrombinase
OT  - Rivaroxaban
OT  - Thiophenes
OT  - Thrombin Generation
OT  - Thrombosis
EDAT- 2015/12/22 06:00
MHDA- 2016/11/05 06:00
CRDT- 2015/12/22 06:00
PHST- 2015/12/22 06:00 [entrez]
PHST- 2015/12/22 06:00 [pubmed]
PHST- 2016/11/05 06:00 [medline]
AID - 10.1586/17474086.2016.1135046 [doi]
PST - ppublish
SO  - Expert Rev Hematol. 2016;9(2):115-22. doi: 10.1586/17474086.2016.1135046.